Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib (Dux)
Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab (Erbitux) and Erlotinib (Tarceva) in Patients With Chemotherapy-refractory Colorectal Cancer
Sponsor: Austin Health
Listed as NCT00784667, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains ongoing. Sponsored by Austin Health, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Austin Health
- Ballarat Health Services
- Queen Elizabeth Hospital, Adelaide
- Royal North Shore Hospital
For direct contact, visit the study record on ClinicalTrials.gov .